Modality
Small Molecule
MOA
CAR-T BCMA
Target
PI3Kα
Pathway
Lipid Met
NSCLC
Development Pipeline
Preclinical
Feb 2020
→ Jun 2027
PreclinicalCurrent
NCT04030226
1,248 pts·NSCLC
2020-02→2027-06·Not yet recruiting
1,248 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2027-06-231.2y awayInterim· NSCLC
Trial Timeline
2020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3
Preclinical
Not yet…
Catalysts
Interim
2027-06-23 · 1.2y away
NSCLC
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04030226 | Preclinical | NSCLC | Not yet recr... | 1248 | DOR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Voxacilimab | Pfizer | Phase 2 | TYK2 | |
| Voxaderotide | Johnson & Johnson | NDA/BLA | PI3Kα | |
| Rimamavacamten | Merck & Co | Phase 1 | PI3Kα | |
| NVO-9087 | Novo Nordisk | Phase 1/2 | Tau | |
| Fixazanubrutinib | Amgen | Phase 2 | PI3Kα | |
| REG-8074 | Regeneron | Phase 2/3 | KRASG12C | |
| GMA-1468 | Genmab | NDA/BLA | PI3Kα | |
| JAZ-8729 | Jazz Pharma | Phase 2/3 | FcRn | |
| 369-789 | Hansoh Pharma | Phase 3 | PI3Kα | |
| Mavutuximab | Hansoh Pharma | Phase 2/3 | PI3Kα |